Research.Patient.info
Melanoma Stage III or IV research hub
2 indexed studies · 1 currently recruiting
- enrolling by invitation
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
This study looks at how immunotherapy for melanoma might affect the heart in the long term. Researchers want to see if it's possible to check for heart-related side effects years after treatment, hoping to improve future care for patients.
United Kingdom - active not recruitingPHASE1, PHASE2
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.
Germany · Spain · United Kingdom